Since the development of immunological checkpoints, the programmed cell death protein 1/ligand-1 (PD-1/PD-L1) pathway has emerged as an exciting therapeutic target for patients with advanced bladder cancer (Eckstein et al., 2019). Here, PDCD1 is linked to urinary bladder carcinoma.